摘要:
A quinoline-N-oxide derivative represented by the formula: ##STR1## wherein X is hydroxy, lower alkoxy, lower alkylthio, unsubstituted or substituted aralkyloxy, or unsubstituted or substituted aralkylthio; Y is a hydrogen atom or halogen atom; R.sub.1 is alkylene or alkenylene having 3 to 15 carbon atom; Z is hydroxymethyl, lower alkoxymethyl, unsubstituted or substituted aryloxymethyl, tetrahydropyranyloxymethyl, tetrahydrofuranyloxymethyl, unsubstituted or substituted arylsulfonyloxymethyl, lower alkylthiomethyl, unsubstituted or substituted arylthiomethyl, lower alkylsulfinylmethyl, unsubstituted or substituted arylsulfinylmethyl, lower alkylsulfonylmethyl, unsubstituted or substituted arylsulfonylmethyl, aminomethyl, --CH.sub.2 NHR.sub.2 (wherein R.sub.2 is lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl), --CH.sub.2 NR.sub.3 R.sub.4 (wherein R.sub.3 and R.sub.4 are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl), --CH.sub.2 N.sup.+ R.sub.5 R.sub.6 R.sub.7 (wherein R.sub.5, R.sub.6, and R.sub.7 are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl, where the counterion is an anion of acid or a hydroxyl ion), --COR.sub.8 (wherein R.sub.8 is a hydrogen atom, lower alkyl or hydroxy), --CH(OR.sub.9).sub.2 (wherein R.sub.9 is lower alkyl), iminomethyl, hydroxyiminomethyl, or a halogen atom and its salts, can very strongly inhibit the lipoxygenase and considerably suppress production and release of its metabolites, and thus are useful as preventive and healing agents for the diseases caused by the lipoxygenase metabolites.
摘要翻译:由下式表示的喹啉-N-氧化物衍生物:其中X为羟基,低级烷氧基,低级烷硫基,未取代或取代的芳烷氧基,或未取代或取代的芳烷硫基; Y是氢原子或卤素原子; R1是具有3至15个碳原子的亚烷基或亚烯基; Z是羟甲基,低级烷氧基甲基,未取代或取代的芳氧基甲基,四氢吡喃氧基甲基,四氢呋喃氧基甲基,未取代或取代的芳基磺酰氧基甲基,低级烷硫基甲基,未取代或取代的芳基硫代甲基,低级烷基亚磺酰基甲基,未取代或取代的芳基亚磺酰基甲基,低级烷基磺酰基甲基,未取代或取代的芳基磺酰基甲基,氨基甲基,-CH2NHR2( 其中R 2是低级烷基,未取代或取代的芳烷基或未取代或取代的芳基),-CH 2 NR 3 R 4(其中R 3和R 4是低级烷基,未取代或取代的芳烷基,或未取代或取代的芳基),-CH 2 N + R 5 R 6 R 7(其中R 5,R 6 ,R 7为低级烷基,未取代或取代的芳烷基或未取代或取代的芳基,其中抗衡离子为酸或羟基离子的阴离子),-COR8(其中R8为氢原子,低级烷基或羟基),-CH (OR 9)2(其中R 9为低级烷基),亚氨基甲基,羟基亚氨基甲基或卤素 原子及其盐可以非常强烈地抑制脂氧合酶,并显着抑制其代谢物的产生和释放,因此可用作由脂氧合酶代谢物引起的疾病的预防和治疗剂。
摘要:
A preventive and healing composition for diseases due to lipoxygenase metabolic products, which comprises an effective amount of a compound represented by the formula: ##STR1## wherein R is an alkyl group having 1 to 15 carbon atoms and at least one pharmaceutically acceptable carrier.
摘要:
Phosphorus-containing oligopeptide derivatives are prepared by synthetic methods. The compounds exhibit angiotensin converting enzyme-inhibiting action and are, therefore, useful as anti-hypertensive agents.
摘要:
Disclosed is a novel physiologically active substance, K-26, a process for preparation thereof and a pharmaceutical composition containing the same. The composition of matter, K-26, is useful as a hypotensive agent.
摘要:
A hydroxamic acid compound represented by the general formula (I) or a salt thereof; ##STR1## wherein R.sup.1 represents a hydrogen atom, or a substituted or unsubstituted alkanoyl group, R.sup.2 represents an unsubstituted alkanoyl, substituted lower alkanoyl or substituted lower alkyl group, and m represents an integer of 3 to 7, which are useful for the prevention and/or treatment of diseases caused by lipoxygenase-mediated metablites.
摘要:
The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof, represented by Formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl, R.sup.4 represents lower alkyl, or substituted or unsubstituted aryl, R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R.sup.5 and R.sup.6 are combined together to represent --O--(CH.sub.2)p--O-- (p is an integer of 1 to 3), n represents 0, 1, or 2, and m represents 1 or 2. The compounds of the present invention have an adenosine A.sub.2 receptor antagonistic activity, and are useful for the treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A.sub.2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).
摘要:
A network system according to an implementation of the present invention involves: determining whether or not a matching address is found by comparing (i) an apparatus address, of an apparatus connected to an HDMI network, which is obtained via the HDMI network with (ii) an apparatus address, of an apparatus connected to another network, which is obtained via the other network (S44). Here, the matching address represents a match between the apparatuses addresses. When determining that the matching address is found, the implementation of the present invention involves determining that the terminal apparatus having the matching address is connected to a control apparatus via both of the HDMI network and the other network (S46).
摘要:
Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
摘要:
Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.